The global demand for Orally Disintegrating Tablet Market is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2019 with a CAGR of XX% under the study period of 2020 - 2026.
Orally Disintegrating Tablet is a solid drug dosage that can dissolve or disintegrate in the patient's mouth within 60 seconds without water. It is a preferred alternative to conventional tablets and capsules. They are a good alternative for patients with difficulty swallowing, who experience nausea and vomiting, patients who suffer from neurological disorders including older adults and kids. These tablets provide accurate dosing, pre gastric absorption of drugs and are quickly absorbed into the blood circulation. They are taste-masked using microparticles to avoid the bitter aftertaste. Orally disintegrating tablets can be considered a patient-centric drug delivery mechanism that are quite robust with multiple drug packaging configurations and high drug loading capability.
The growth of this market is driven by the rise in the adoption of a compliant drug form by the geriatric and paediatric population. There is a rise in diseases associated with the central nervous system which can affect the conventional drug handling capacity of the patients. Hence this segment can lead to a high gain in the market. Increased acceptance of technologically advanced products and a rise in awareness can boost the market. The main challenging factor is the hurdles in the formulation of high doses for orally disintegrating tablets.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of orally disintegrating tablet.
The entire orally disintegrating tablet market has been sub-categorized into drug class, disease indication and distribution channel. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Drug Class
By Disease Indication
- CNS Stimulants
- Anti-Parkinsonian Drugs
- Anti-Allergy Drugs
- Proton Pump Inhibitors
By Distribution Channel
- CNS Diseases
- GI Diseases
- CVS Disorders
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
This section covers regional segmentation which accentuates on current and future demand for orally disintegrating tablet market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Orally Disintegrating Tablet Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the orally disintegrating tablet market include Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bausch Health, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Others. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers& acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.